Cancer arising from nerve tissue, classified as a soft-tissue sarcoma of neurogenic origin.
During active treatment, medical records confirming the diagnosis and documenting your ongoing surgical, radiation, or chemotherapy treatment are the central evidence. Records showing the dates treatment began and ended matter because they establish when the 6-month continuation period starts and stops.
Once treatment ends, VA will look for evidence of recurrence or spread. Imaging studies, biopsy results, oncology notes, and lab work that show no local recurrence and no metastases support a transition to residual-based rating at the 6-month mark. If recurrence or spread is found, records documenting that finding would be relevant to continued rating.
After the transition to residuals, the evidence needed depends on what lasting impairments you have. For example, nerve-related residuals would be supported by neurological exam findings, electrodiagnostic test results, and statements from you or those who know you describing how the remaining symptoms affect your work and daily activities.
Conditions that are often caused or made worse by this one. If you have any of these, they may be claimable as secondary service connection.
